Morphosys Company Profile Get Rating News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Morphosys company profile get rating. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Morphosys Company Profile Get Rating Today - Breaking & Trending Today

The Goldman Sachs Group Analysts Give MorphoSys (ETR:MOR) a €24.00 Price Target

MorphoSys (ETR:MOR – Get Rating) has been given a €24.00 ($25.81) price target by stock analysts at The Goldman Sachs Group in a research report issued on Friday, Borsen Zeitung reports. The Goldman Sachs Group’s target price points to a potential upside of 15.33% from the company’s current price. Several other brokerages also recently weighed […] ....

United States , Borsen Zeitung , Berenberg Bank , Deutsche Bank Rese , Deutsche Bank Aktiengesellschaft , Jpmorgan Chase Co , Morphosys Company Profile Get Rating , Goldman Sachs Group , Get Rating , Bank Aktiengesellschaft , Bank Rese , Sys Company Profile , Petr Mor , Set Price Target , The Goldman Sachs Group Inc ,

MorphoSys (NASDAQ:MOR) Lowered to Hold at Zacks Investment Research

MorphoSys (NASDAQ:MOR – Get Rating) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Saturday, Zacks.com reports. According to Zacks, “MorphoSys AG is a biopharmaceutical company. It develops treatment for cancer, inflammations and autoimmune diseases. The company’s proprietary portfolio consists of MOR208, MOR202, MOR103, […] ....

United States , Capricorn Fund Managers Ltd , Morgan Stanley , Berenberg Bank , Goldman Sachs Group Inc , Zacks Investment Research , Deutsche Bank Aktiengesellschaft , Susquehanna International Group , Alphacentric Advisors , Morphosys Company Profile Get Rating , Millennium Management , Get Rating , Fund Managers Ltd , Centric Advisors , Sachs Group , International Group , Sys Company Profile , Nasdaq Mor ,

MorphoSys AG (ETR:MOR) Receives Consensus Recommendation of "Buy" from Analysts

MorphoSys AG (ETR:MOR – Get Rating) has been given a consensus rating of “N/A” by the seven brokerages that are currently covering the company, Marketbeat Ratings reports. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is €55.14 ($59.94). MOR has been the topic […] ....

United States , Jpmorgan Chase Co , Berenberg Bank , Morphosys Company Profile Get Rating , Deutsche Bank Aktiengesellschaft , Get Rating , Marketbeat Ratings , Bank Aktiengesellschaft , Sys Company Profile , Petr Mor ,

MorphoSys AG (NASDAQ:MOR) Receives Consensus Rating of "Hold" from Analysts

Shares of MorphoSys AG (NASDAQ:MOR – Get Rating) have earned an average rating of “Hold” from the fourteen research firms that are covering the company, MarketBeat reports. Eleven investment analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 1-year price target among brokers […] ....

United States , Morgan Stanley , Berenberg Bank , Zacks Investment Research , Blackrock Inc , Alphacentric Advisors , Morphosys Company Profile Get Rating , Cubist Systematic Strategies , Get Rating , Investment Research , Systematic Strategies , Sys Company Profile , Nasdaq Mor ,

MorphoSys (NASDAQ:MOR) Price Target Cut to €40.00

MorphoSys (NASDAQ:MOR – Get Rating) had its target price lowered by analysts at Morgan Stanley from €50.00 ($54.95) to €40.00 ($43.96) in a research note issued to investors on Monday, The Fly reports. The brokerage currently has an “equal weight” rating on the stock. A number of other research analysts have also commented on the […] ....

United States , Morgan Stanley , Berenberg Bank , Zacks Investment Research , Deutsche Bank Aktiengesellschaft , Blackrock Inc , Alphacentric Advisors , Morphosys Company Profile Get Rating , Millennium Management , Get Rating , Bank Aktiengesellschaft , Investment Research , Bay Capital Management , Sys Company Profile , Nasdaq Mor , Lower Price Target ,